Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Low expression of ACLY associates with favorable prognosis in acute myeloid leukemia

Fig. 1

Survival analyses of patients with AML. Kaplan–Meier estimates of OS by high and low ACLY expression for AML patients (a), cytogenetically intermediate AML (b) cytogenetically normal AML (c), and stratification of distinct ACLY levels and treatment protocols (d), respectively. The protocols include homoharringtonine-based regiment (HAA), daunorubicin and cytarabine (DA), idarubicin and aclarubicin (IA)

Back to article page